A study supported by the Alzheimer’s Drug Discovery Foundation and published today in JAMA Network Open provides the first evidence that rotigotine, a drug that acts on dopamine transmission in the brain, improves cognitive function in patients with mild-to-moderate Alzheimer’s disease.
While rotigotine did not show a significant effect on memory functions, the drug improved frontal lobe executive function and patients’ ability to perform activities of daily living. The randomized clinical trial, Effects of Dopaminergic Therapy in Patients with Alzheimer’s Disease (DOPAD), was led by Giacomo Koch, M.D., Ph.D., a neurologist at the Santa Lucia Foundation in Rome, in collaboration with Alessandro Martorana, M.D. of the University of Tor Vergata…
